In 2022, the ACR, alongside the European Alliance of Associations for Rheumatology (EULAR), revised the classification criteria to include the following clinical, laboratory, biopsy components and associated scores: obstructive airway disease (+ 3), nasal polyps (+ 3), mononeuritis multiplex (+ 1), blood eosinophils count ≥ 1 × 109/L (+ 5), extravascular eosinophilic-predominant inflammation on biopsy (+ 2), positive cANCA or anti-PR3 antibody (-3), and hematuria (-1) [4]. Here, PRTN3 is linked to nasal cavity polyp.